Results 171 to 180 of about 320,824 (239)

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk   +12 more
wiley   +1 more source

Electrosurgical Tangential Decortication for Severe Rhinophyma: A Case Report. [PDF]

open access: yesCureus
Shuchleib Cukiert M   +4 more
europepmc   +1 more source

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera   +12 more
wiley   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies   +23 more
wiley   +1 more source

Ribosome Biogenesis as a Putative Bottleneck to Skeletal Muscle Hypertrophy: Mechanisms, Human Evidence, and Practical Modulators. [PDF]

open access: yesCells
Muñoz López M   +4 more
europepmc   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li   +12 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy